ProMIS Neurosciences reports 2022 net loss $18.1M, cash $5.9M, IND for PMN310 expected in 60 days

ProMIS Neurosciences Inc.

Net loss $18.1M in 2022 vs $9.8M in 2021; cash $5.9M vs $16.9M.
R&D expenses rose to $16.1M from $4.6M, driven by PMN310 IND preparation.
IND for Alzheimer's candidate PMN310 expected within 60 days; Phase 1a planned.
Completed GLP toxicology for PMN310; no adverse effects at 5x planned highest dose.
Discovery programs: PMN267 (ALS) and PMN442 (MSA) selected and humanized.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the year ended December 31, 2022 results: net income Net loss was $18.1 million for the year ended December 31, 2022, compared to $9.8 million for the same period in 2021..

Period: the year ended December 31, 2022
Net income: Net loss was $18.1 million for the year ended December 31, 2022, compared to $9.8 million for the same period in 2021.
Result: reported results

Exact text from the filing

reporting its financial condition and financial results as of and for the year ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-003169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.